Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib as an Add-on Treatment for OCD
NCT04786548Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Apr 2021
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of celecoxib oral solution in obsessive compulsive disorder (OCD), sponsored by New York State Psychiatric Institute. Started Apr 2021; status: completed.
02
Drugs
celecoxib oral solution
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT04786548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04786548.